ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Company Country Ticker View
Hana Pharm. Co., Ltd. Logo
Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.
South Korea 293480
Hanmi Pharm. Co., Ltd. Logo
Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.
South Korea 128940
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden HNSA
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan 4593
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan 219A
HELLENIC DYNAMICS PLC Logo
Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.
United Kingdom HELD
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom HEMO
HEM Pharma Inc. Logo
Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.
South Korea 376270
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland HMP
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland HRTIS

Talk to a Data Expert

Have a question? We'll get back to you promptly.